Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 2, 2013, Pages 290-301

  Van De Wiele, Christophe ^a   Kruse, Vibeke ^a   Smeets, Peter ^a   Sathekge, Mike ^b   Maes, Alex ^c,d  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF PRETORIA   (South Africa)

^c AZ Groeninge ^*  (Belgium)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Metabolic tumour volume; Solid tumours; Total lesion glycolysis

Indexed keywords

LACTATE DEHYDROGENASE;

CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE FREE SURVIVAL; ENDOMETRIUM CARCINOMA; ESOPHAGUS CARCINOMA; GLYCOLYSIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG CARCINOMA; LUNG SMALL CELL CANCER; NASOPHARYNX CARCINOMA; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; REVIEW; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; TREATMENT RESPONSE; TUMOR VOLUME; UTERINE CERVIX CARCINOMA;

CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; GENITAL NEOPLASMS, FEMALE; GLYCOLYSIS; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; MEDICAL ONCOLOGY; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84874112852     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2280-z     Document Type: Review

References (82)

1. Murchison JT. TNM staging update for lung cancer: why is this important? World J Radiol. 2012;4:126-7.
2. Ball DL, Fisher R, Burmeister B, Graham P, Joseph D, Penniment M, et al. Stage is not a reliable indicator of tumor volume in non-small cell lung cancer: a preliminary analysis of the Trans-Tasman Radiation Oncology Group 99-05 database. J Thorac Oncol. 2006;1:667-72.
3. Doweck I, Denys D, Robbins KT. Tumor volume predicts outcome for advanced head and neck cancer treated with targeted chemoradiotherapy. Laryngoscope. 2002;112:1742-9.
4. Plataniotis GA, Theofanopoulou ME, Kalogera-Fountzila A, Haritanti A, Ciuleanou E, Ghilezan N, et al. Prognostic impact of tumor volumetry in patients with locally advanced head-and-neck carcinoma (non-nasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial. Int J Radiat Oncol Biol Phys. 2004;59:1018-26.
5. Frings V, de Langen AJ, Smit EF, van Velden FH, Hoekstra OS, van Tinteren H, et al. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer. J Nucl Med. 2010;51:1870-7.
6. Cheebsumon P, van Velden FH, Yaqub M, Hoekstra CJ, Velasquez LM, Hayes W, Hoekstra OS, et al. Measurement of metabolic tumor volume: static versus dynamic FDG scans. EJNMMI Res. 2011;1:35.
7. American Cancer Society. Cancer Facts and Figures. www.cancer.org/ Research/CancerFactsFigures/Index. Accessed 2 Nov 2012.
8. van der Schroeff MP, Baatenburg de Jong RJ. Staging and prognosis in head and neck cancer. Oral Oncol. 2009;45:356-60.
9. Xie P, Li M, Zhao H, Sun X, Fu Z, Yu J. 18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: a meta-analysis. J Cancer Res Clin Oncol. 2011;137:1085-93.
10. Gupta T, Master Z, Kannan S, Agarwal JP, Ghsoh-Laskar S, Rangarajan V, et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38:2083-95.
11. Chung MK, Jeong HS, Son YI, So YK, Park GY, Choi JY, et al. Metabolic tumor volumes by [18F]-fluorodeoxyglucose PET/CT correlate with occult metastasis in oral squamous cell carcinoma of the tongue. Ann Surg Oncol. 2009;16:3111-7.
12. Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med. 2012;53:709-15.
13. Moon SH, Choi JY, Lee HJ, Son YI, Baek CH, Ahn YC, et al. Prognostic value of (18)F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparisons of volume-based metabolic parameters. Head Neck. 2012. doi: 10.1002/hed.22904.
14. Chan SC, Chang JT, Lin CY, Ng SH, Wang HM, Liao CT, et al. Clinical utility of 18F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma: predictive role for different survival endpoints and impact on prognostic stratification. Nucl Med Commun. 2011;32:989-96.
15. Xie P, Yue JB, Zhao HX, Sun XD, Kong L, Fu Z, et al. Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2010;136:883-9.
16. Kao CH, Lin SC, Hsieh TC, Yen KY, Yang SN, Wang YC, et al. Use of pretreatment metabolic tumour volumes to predict the outcome of pharyngeal cancer treated by definitive radiotherapy. Eur J Nucl Med Mol Imaging. 2012;39:1297-305.
17. Chung MK, Jeong HS, Park SG, Jang JY, Son YI, Choi JY, et al. Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res. 2009;15:5861-8.
18. La TH, Filion EJ, Turnbull BB, Chu JN, Lee P, Nguyen K, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009;74:1335-41.
19. Tang C, Murphy JD, Khong B, La TH, Kong C, Fischbein NJ, et al. Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012;83:1514-20.
20. Deron P, Mertens K, Goethals I, Rottey S, Duprez F, De Neve W, et al. Metabolic tumour volume. Prognostic value in locally advanced squamous cell carcinoma of the head and neck. Nuklearmedizin. 2011;50:141-6.
21. Murphy JD, La TH, Chu K, Quon A, Fischbein NJ, Maxim PG, et al. Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011;80:514-21.
22. Seol YM, Kwon BR, Song MK, Choi YJ, Shin HJ, Chung JS, et al. Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy. Acta Oncol. 2010;49:201-8.
23. Romesser PB, Qureshi MM, Shah BA, Chatburn LT, Jalisi S, Devaiah AK, et al. Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy. Ann Nucl Med. 2012;26:527-34.
24. Mountain CF. A new international staging system for lung cancer. 1986. Chest. 2009;136(5 Suppl):e25.
25. Cogen A, Dockx Y, Cheung K, Meulemans E, Lauwers P, Nia P, et al. TNM-classification for lung cancer: from the 7th to the 8th edition. Acta Chir Belg. 2011;111:389-92.
26. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122:1037-57.
27. Yip D, Harper PG. Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer. 2000;28:173-85.
28. de Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WJ. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer. 2007;110:1654-64.
29. Lee P, Weerasuriya DK, Lavori PW, Quon A, Hara W, Maxim PG, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys. 2007;69:328-33.
30. Lee P, Bazan JG, Lavori PW, Weerasuriya DK, Quon A, Le QT, et al. Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer. Clin Lung Cancer. 2012;13:52-8.
31. Yan H, Wang R, Zhao F, Zhu K, Jiang S, Zhao W, et al. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy. Acta Radiol. 2011;52:646-50.
32. Liao S, Penney BC, Zhang H, Suzuki K, Pu Y. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in stage IV nonsurgical small-cell lung cancer. Acad Radiol. 2012;19:69-77.
33. Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39:27-38.
34. Zhang H, Wroblewski K, Appelbaum D, Pu Y. Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer. Int J Comput Assist Radiol Surg. 2012. doi: 10.1007/s11548-012-0749-7.
35. Kim K, Kim SJ, Kim IJ, Kim YS, Pak K, Kim H. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer. Nucl Med Commun. 2012;33:613-20.
36. Meng X, Sun X, Mu D, Xing L, Ma L, Zhang B, et al. Noninvasive evaluation of microscopic tumor extensions using standardized uptake value and metabolic tumor volume in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;82:960-6.
37. Huang W, Zhou T, Ma L, Sun H, Gong H, Wang J, et al. Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2011;38:1628-35.
38. Zhu D, Ma T, Niu Z, Zheng J, Han A, Zhao S, Yu J. Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer. Lung Cancer. 2011;73:332-7.
39. Oh JR, Seo JH, Chong A, Min JJ, Song HC, Kim YC, et al. Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39:925-35.
40. van Loon J, Offermann C, Ollers M, van Elmpt W, Vegt E, Rahmy A, et al. Early CT and FDG-metabolic tumour volume changes show a significant correlation with survival in stage I-III small cell lung cancer: a hypothesis generating study. Radiother Oncol. 2011;99:172-5.
41. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
42. Pennathur A, Luketich J. Resection of esophageal cancer: strategies for optimal management. Ann Thorac Surg. 2008;85:751-6.
43. Sagar PM, Gauperaa T, Sue-Ling H, McMahon MJ, Johnston D. An audit of the treatment of cancer of the oesophagus. Gut. 1994;35:941-5.
44. Lordick F, Ott K, Sendler A. Gastric cancer and adenocarcinoma of the esophagogastric junction: principles of neoadjuvant therapy. Chirurg. 2011;82:968-73.
45. Zhu W, Xing L, Yue J, Sun X, Sun X, Zhao H, et al. Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation: a systematic review and meta-analysis. Br J Radiol. 2012;85:e694-701.
46. Downey RJ, Akhurst T, Ilson D, Ginsburg R, Bains M, Gonen M, et al. Whole body 18FDG PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol. 2003;21:428-32.
47. Flamen P, Van Cutsem E, Lerut A, Cambier J, Haustermans K, Bormans G, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol. 2002;13:361-8.
48. Javeri H, Xiao L, Rohren E, Lee J, Liao Z, Hofstetter W, et al. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer. 2009;115:5184-92.
49. Levine E, Farmer M, Clark P, Mishra G, Ho C, Geisinger K, et al. Predictive value of 18-fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg. 2006;243:472-8.
50. Swisher S, Erasmus J, Maish M, Correa A, Macapinlac H, Ajani J, et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004;101:1776-85.
51. Vallbohmer D, Holscher A, Dietlein M, Bollschweiler E, Baldus S, Mönig S, et al. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg. 2009;250:888-94.
52. Kim M, Ryu J, Kim S, Ahn J, Kim S, Park S, et al. Value of complete metabolic response by 18F-fluorodeoxyglucose-psoitron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer. 2007;43:1385-91.
53. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797-805.
54. Zhong X, Yu J, Zhang B, Mu D, Zhang W, Li D, et al. Using 18F-fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2009;73:136-41.
55. Mamede M, El Fakhri G, Abreu-e-Lima P, Gandler W, Nosé V, Gerbaudo VH. Pre-operative estimation of esophageal tumor metabolic length in FDG-PET images with surgical pathology confirmation. Ann Nucl Med. 2007;21:553-62.
56. Roedl JB, Harisinghani MG, Colen RR, Fischman AJ, Blake MA, Mathisen DJ, et al. Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography. Ann Thorac Surg. 2008;86:1131-8.
57. I HS, Kim SJ, Kim IJ, Kim K. Predictive value of metabolic tumor volume measured by 18F-FDG PET for regional lymph node status in patients with esophageal cancer. Clin Nucl Med. 2012;37:442-6.
58. Hyun SH, Choi JY, Shim YM, Kim K, Lee SJ, Cho YS, et al. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol. 2010;17:115-22.
59. Mamede M, Abreu-E-Lima P, Oliva MR, Nosé V, Mamon H, Gerbaudo VH. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results. Am J Clin Oncol. 2007;30:377-88.
60. Jayachandran P, Pai RK, Quon A, Graves E, Krakow TE, La T, et al. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;84:471-7.
61. Roedl JB, Colen RR, Holalkere NS, Fischman AJ, Choi NC, Blake MA. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation. Radiother Oncol. 2008;89:278-86.
62. Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004;22:872-80.
63. Kidd EA, Grigsby PW. Intratumoral metabolic heterogeneity of cervical cancer. Clin Cancer Res. 2008;14:5236-41.
64. Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer. 2007;110:1738-44.
65. Kidd EA, Thomas M, Siegel BA, Dehdashti F, Grigsby PW. Changes in cervical cancer FDG uptake during chemoradiation and association with response. Int J Radiat Oncol Biol Phys. 2012. doi: 10.1016/j.ijrobp.2012.02.056.
66. Chung HH, Kim JW, Han KH, Eo JS, Kang KW, Park NH, et al. Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer. Gynecol Oncol. 2011;120:270-4.
67. Sharma DN, Rath GK, Kumar R, Malhotra A, Kumar S, Pandjatcharam J, et al. Positron emission tomography scan for predicting clinical outcome of patients with recurrent cervical carcinoma following radiation therapy. J Cancer Res Ther. 2012;8:23-7.
68. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005;366:491-505.
69. Liu FY, Chao A, Lai CH, Chou HH, Yen TC. Metabolic tumor volume by 18F-FDG PET/CT is prognostic for stage IVB endometrial carcinoma. Gynecol Oncol. 2012;125:566-71.
70. Chung HH, Kwon HW, Kang KW, Park NH, Song YS, Chung JK, et al. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. Ann Surg Oncol. 2012;19:1966-72.
71. Okada M, Shimono T, Komeya Y, Ando R, Kagawa Y, Katsube T, et al. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions. Ann Nucl Med. 2009;23:349-54.
72. Tann M, Sandrasegaran K, Jennings S, Skandarajah A, McHenry L, Schmidt C. Positron-emission tomography and computed tomography of cystic pancreatic masses. Clin Radiol. 2007;62:745-51.
73. Orlacchio A, Schillaci O, Antonelli L, D'Urso S, Sergiacomi G, Nicoli P, Simonetti G. Solitary pulmonary nodules: morphological and metabolic characterisation by FDG-PET-MDCT. Radiol Med. 2007;112:157-73.
74. Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. Visual and semiquantitative analyses for F-18 fluorodeoxyglucose PET scanning in pulmonary nodules 1 cm to 3 cm in size. Ann Thorac Surg. 2005;79:948-88.
75. Kang W, Chung J, So Y, Jeong J, Lee D, Lee M. Differentiation of mediastinal FDG uptake observed in patients with non-thoracic tumours. Eur J Nucl Med Mol Imaging. 2004;31:202-7.
76. Nakamoto Y, Higashi T, Sakahara H, Ishimori T, Kobayahsi H, Ishizu K, et al. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer. 2000;89:2547-54.
77. Erdi Y, Mawlawi O, Larson S, Imbriaco M, Yeung H, Finn R, Humm J. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer. 1997;15:2505-20509.
78. Zasadny K, Kison P, Francis R, Wahl R. FDG-PET determination of metabolically active tumor volume and comparison with CT. Clin Positron Imaging. 1998;1:123-9.
79. Murphy JD, Chisholm KM, Daly ME, Wiegner EA, Truong D, Iagaru A, et al. Correlation between metabolic tumor volume and pathologic tumor volume in squamous cell carcinoma of the oral cavity. Radiother Oncol. 2011;101:356-61.
80. Biehl KJ, Kong FM, Dehdashti F, Jin JY, Mutic S, El Naqa I, et al. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate? J Nucl Med. 2006;47:1808-12.
81. Minn H, Clavo AC, Grénman R, Wahl RL. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med. 1995;36:252-8.
82. Minn H, Clavo AC, Wahl RL. Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging. Nucl Med Biol. 1996;23:941-6.